The U.S. Food and Drug Administration have approved the use of a drug derived from marijuana for the first time Monday, giving the go ahead to treat two rare forms of epilepsy with the compound cannabidiol, also known as CBD, found in hemp and marijuana.
Epidiolex, a form of cannabidiol, will be legally used to treat Lennox-Gastaut syndrome and Dravet syndrome, two serious and rare kinds of epilepsy. Epidiolex is the first approved treatment for Dravet syndrome, according to the FDA.
Sativa Investments (LON:SATI), seeks to invest in companies which are well-placed to take advantage of the dynamic regulatory environment surrounding medical Cannabis. Our investment strategy focuses on production, pharmacology, testing and compliance, R&D commercialisation, and sales and marketing. The Directors are already engaging with possible target investments in their key areas of interest.